Macular Disease Expert Witness

The Medical-Legal Question in Macular Cases

The macula is only a few millimeters across, yet it carries most of what patients and juries mean by "vision." The recurring legal questions are whether macular disease was detected when it should have been, whether treatment and monitoring followed accepted intervals, and how much of the final acuity reflects the natural course of the disease rather than any delay. Optical coherence tomography (OCT) — a cross-sectional retinal scan performed at nearly every retina visit — makes the macula one of the best-documented structures in medicine, which gives these cases an unusually objective evidentiary base.

Age-Related Macular Degeneration and Anti-VEGF Timing

AMD occurs in a dry (atrophic) form, which usually progresses slowly, and a wet (neovascular) form, in which abnormal vessels leak fluid and blood under the macula. Wet AMD is treated with intravitreal injections of anti-VEGF (anti–vascular endothelial growth factor) medication, typically on recurring schedules guided by OCT findings. Litigation themes include delayed recognition of conversion from dry to wet disease, gaps between injections during active leakage, monitoring of the fellow eye in a patient who has lost one eye to AMD, and follow-up systems for patients who miss appointments. The counter-considerations are equally real: wet AMD can destroy central vision quickly despite fully appropriate care, dry AMD progresses without any currently reversible treatment for most patients, and missed visits are sometimes attributable to the patient rather than the practice.

Macular Holes, Epiretinal Membrane, and Central Serous

A macular hole is a full-thickness defect in the central retina, usually repaired by vitrectomy; duration and hole size influence surgical prognosis, so diagnostic delay can matter. An epiretinal membrane is a sheet of scar tissue on the macular surface causing distortion; it typically progresses slowly, and surgery is elective, which limits many delay theories. Central serous chorioretinopathy involves fluid accumulation under the macula, often in younger patients and classically associated with corticosteroid exposure; it frequently resolves without treatment, but recurrent or chronic disease can cause permanent change. Each condition has a distinct natural history, and a credible opinion matches the causation analysis to the specific diagnosis rather than treating "macular disease" as one entity.

Medication-Related Maculopathy

Drug toxicity to the macula — most prominently hydroxychloroquine maculopathy and its screening requirements — is addressed on the dedicated ocular toxicity expert witness page, since the standard-of-care questions there center on monitoring-guideline adherence across specialties.

Limitations of the Evaluation

Serial OCT allows precise reconstruction of macular anatomy over time, but anatomy and function do not correlate perfectly: some eyes see better than their scans suggest, others worse. Visual outcome projections for AMD carry genuine statistical spread, and an honest report frames them as probabilities, not certainties. Where records lack imaging or acuity data at key dates, the expert must say what cannot be determined. The frameworks on the causation and standard of care pages apply throughout.

What Attorneys Should Provide

Complete retina-specialist records including every OCT scan and angiogram in native or exported image form, the injection log with dates and medications, optometry and general ophthalmology records establishing baseline vision, and any correspondence about missed or rescheduled appointments. The guide on OCT evidence explains what these scans can show a fact-finder.

Frequently Asked Questions